Similarly, a mitoNEET ligand, TT01001, which was designed based on the structure of pioglitazone, was reported to show the same potency as pioglitazone in improving hyperglycemia, hyperlipidemia, and glucose intolerance in diabetic (db/db) mice by significantly suppressing the elevated mitochondrial complex activity of skeletal muscles, without activating PPARγ or causing weight gain [40]. The gene discussed is PPARG; the disease is Hyperglycemia.